Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Caristo Diagnostics | 2024 | Venture - Series Unknown | $150K | Oxford |
| Greywolf Therapeutics | 2024 | Series B | $50.0M | Abingdon |
| Oxford Endovascular | 2024 | Series A | $10.2M | Oxford |
| Proxisense | 2023 | Series A | $1.3M | Oxford |
| Prolific | 2023 | Series A | $32.3M | Oxford |
| OMass Therapeutics | 2023 | Series B | $12.5M | Oxford |
| Quantrol Ox | 2023 | Seed | $3.7M | Espoo |
| Beacon Therapeutics | 2026 | Series C | $75.0M | Alachua |
| Albus Health | 2023 | Venture - Series Unknown | Undisclosed | Oxford |
| Alethiomics | 2021 | Seed | Undisclosed | Headington |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 26 | Caristo Diagnostics | Venture - Series Unknown | $150K | Oxford, United Kingdom |
| 27 | Greywolf Therapeutics | Series B | $50.0M | Abingdon, United Kingdom |
| 28 | Oxford Endovascular | Series A | $10.2M | Oxford, United Kingdom |
| 29 | Proxisense | Series A | $1.3M | Oxford, United Kingdom |
| 30 | Prolific | Series A | $32.3M | Oxford, United Kingdom |
| 31 | OMass Therapeutics | Series B | $12.5M | Oxford, United Kingdom |
| 32 | Quantrol Ox | Seed | $3.7M | Espoo, Finland |
| 33 | Beacon Therapeutics | Series C | $75.0M | Alachua, United States |
| 34 | Albus Health | Venture - Series Unknown | Undisclosed | Oxford, United Kingdom |
| 35 | Alethiomics | Seed | Undisclosed | Headington, United Kingdom |
Caristo Diagnostics is a biotech company that provides diagnostic platforms for heart diseases, stroke, and diabetes.
We are advancing novel antigen modulation technology that controls T cells to guide the immune system.
Oxford Endovascular are developing a novel treatment for treating brain aneurysms.
Proxisense has developed extreme environment proximity sensors and fluid contamination systems.
Building the most advanced global infrastructure for People Science.
OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics.
QuantrolOx is building automated machine learning-based control software for quantum technologies to tune, stabilize, and optimize qubits.
Beacon Therapeutics is a biotechnology company that develops treatments to preserve and restore vision for rare and prevalent eye diseases.
A med-tech startup that has developed a passive and contactless device for monitoring nocturnal symptoms and environmental metrics at home.
Alethiomics is a biotech company harnessing the power of single-cell multi-omic technology to discover & develop treatment for blood cancer.
Animal Dynamics Ltd, based in Oxford, UK, is a technology company specialising in the design and manufacture of autonomous vehicles.
Perspectum provides imaging solutions to help doctors in clinical decision-making as well as support patient engagement.
Scripta Therapeutics operates as a bio-tech company.
Living Optics is an imaging technology company.
Theolytics is a clinical stage biotechnology company developing next-generation viral therapies.
Fractile is building chips that remove every bottleneck to running large language models at a global scale
Allos is a solution to prognose, monitor, and treat autoimmune conditions.
Archangel Lightworks builds deployable laser communication systems for the space-enabled networks of the future.
Valink Therapeutics develops drug discovery programs focused on bispecific antibody-drug conjugates designed for complex disease biology.
Wild Bioscience is a crop improvement company that provides carbon mitigation, yield enhancement, and farm productivity solutions.
Kneu Health transforms smart phones into clinical-grade monitors to keep a tab on neurological conditions like Parkinson’s and dementia.
Oath Surgical operates with distinction, offering our patients, associates, and partners unmatched value and experiences.
Salience Labs provides photonic switch technology and optical networking solutions tailored for AI infrastructure.
FluoRok is revolutionizing the way fluorochemicals are produced globally.
NavLive creates instant 2D and 3D models, along with accurate site surveys using user-friendly Scan-to-BIM functionality.
Oxford Science Enterprises has invested in 100 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Oxford Science Enterprises's top investment sectors include Health Care, Biotechnology, Therapeutics, Medical, Artificial Intelligence (AI). The firm invests across 49 different industry categories.
Among tracked funding rounds, Beacon Therapeutics received $75.0M in a Series C round. Oxford Science Enterprises's total known invested capital is $1.3B.
Oxford Science Enterprises's average investment size is $20.4M across its portfolio of 100 companies.
Recent Oxford Science Enterprises portfolio additions include Caristo Diagnostics, Greywolf Therapeutics, Oxford Endovascular, Proxisense, Prolific. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors